Merck & Co. Inc. issued an earnings day surprise for investors when it announced on 5 February that it will spin out a handful of older franchises in a new company, leaving Merck with a portfolio dominated by the immuno-oncology blockbuster Keytruda (pembrolizumab).
Executives objected to analyst concerns that Merck going forward will be too dependent on the PD-1 inhibitor, noting during the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
